Stock LNTH LANTHEUS HOLDINGS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases Lantheus Holdings, Inc.

Equities

LNTH

US5165441032

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-04-26 pm EDT 		5-day change 1st Jan Change
65.56 USD +0.55% Intraday chart for Lantheus Holdings, Inc. +2.74% +5.74%
Apr. 18 B. Riley Raises Price Target on Lantheus Holdings to $99 From $95, Keeps Buy Rating MT
Mar. 07 Lantheus Holdings Insider Sold Shares Worth $262,005, According to a Recent SEC Filing MT

Press Releases

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Lantheus to Host First Quarter 2024 Earnings Conference Call and Webcast on May 2, 2024, at 8:00 a.m. Eastern Time
AQ
Lantheus to Host First Quarter 2024 Earnings Conference Call and Webcast on May 2, 2024, at 8:00 a.m. Eastern Time
GL
Lantheus to Present at the Leerink Partners Global Biopharma Conference 2024
GL
Lantheus Announces the FDA Approval of DEFINITY® (Perflutren Lipid Microsphere) for Pediatric Patients
GL
Lantheus Announces Promotion of Amanda Morgan to Chief Commercial Officer
GL
Lantheus Announces Promotion of Amanda Morgan to Chief Commercial Officer
AQ
Lantheus to Present at the TD Cowen 44th Annual Health Care Conference
GL
Lantheus Holdings: Q4 Earnings Snapshot
AQ
Lantheus Reports Fourth Quarter and Full Year 2023 Financial Results
GL
Lantheus Announces Collaboration to Provide Novel Tau Imaging Agent for Large Consortium Clinical Trial Sponsored by the National Institute on Aging
GL
Lantheus to Host Fourth Quarter and Full Year 2023 Earnings Conference Call and Webcast on February 22, 2024, at 8:00 a.m. Eastern Time
GL
Lantheus to Host Fourth Quarter and Full Year 2023 Earnings Conference Call and Webcast on February 22, 2024, at 8:00 a.m. Eastern Time
AQ
Lantheus Announces CEO Succession Plan
GL
Lantheus Announces CEO Succession Plan
AQ
Lantheus Announces Acceptance of its First-to-File ANDA for Generic LUTATHERA® (Lutetium Lu 177 Dotatate)
GL
Lantheus Announces Acceptance of its First-to-File ANDA for Generic LUTATHERA® (Lutetium Lu 177 Dotatate)
AQ
Lantheus Expands Radiopharmaceutical Oncology Pipeline via Strategic Agreements with Perspective Therapeutics
GL
Lantheus Expands Radiopharmaceutical Oncology Pipeline via Strategic Agreements with Perspective Therapeutics
AQ
Lantheus Reports Preliminary Fiscal Year 2023 Revenue
GL
Lantheus Reports Preliminary Fiscal Year 2023 Revenue
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. LNTH Stock
  4. News Lantheus Holdings, Inc.
  5. Press Releases